Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

Astellas’ zolbetuximab combination receives positive CHMP opinion for advanced gastric cancer

Gastric cancer is currently the sixth-most common cause of cancer-related mortality in Europe

- PMLiVE

GSK’s RSV vaccine Arexvy recommended by CHMP for adults aged 50 to 59 years

The positive opinion comes just over a year after Arexvy was approved for those aged 60 and over

- PMLiVE

BioNTech shares promising results for mRNA immunotherapy candidate in advanced melanoma

Melanoma is currently responsible for around 58,000 deaths globally every year

- PMLiVE

Making space to amplify impact

The pharma innovator’s strategic summer resolution

- PMLiVE

The importance of being earnest: supporting healthcare professionals in guiding patients through their journey

How can clinicians tell patients what they need to understand in a way that is accessible, useful, and actionable?

Mednet

- PMLiVE

GSK and Flagship Pioneering partner in deal worth up to $7bn to discover medicines and vaccines

The companies aim to develop a portfolio of up to ten candidates

- PMLiVE

Johnson & Johnson’s Darzalex Faspro regimen approved by FDA for multiple myeloma

More than 35,000 new cases of the blood cancer are expected to be diagnosed in the US this year

- PMLiVE

Boehringer Ingelheim’s Spevigo recommended by CHMP for generalised pustular psoriasis

The chronic neutrophilic inflammatory disease can lead to severe complications, including multisystem organ failure

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug shows continued cognitive improvement in long-term study

Leqembi was granted traditional US approval last year to treat patients in the early stages of the disease

- PMLiVE

Merck and Astellas/Pfizer’s bladder cancer combination receives positive CHMP opinion

More than 165,000 new cases of bladder cancer are diagnosed in the EU every year

- PMLiVE

What’s the difference?

What value does your strategic planning add?

- PMLiVE

Boehringer Ingelheim expands immuno-oncology pipeline with $1.3bn Nerio acquisition

The deal gives the company access to a preclinical immune checkpoint inhibitor programme

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links